Thomson CompuMark, (Boston, MA), a Thomson Reuters business, announced new, proprietary FDA drug sources in its Pharmaceutical XC Search, plus authentic FDA Phonetic Orthographic Computer Analyses (POCAs) of potential marks, both of which reduce the risk of pharmaceutical brand conflicts.
This new content comprises the world’s most comprehensive coverage of drug-related brands and helps companies protect their investment in creating, clearing and registering drug trademarks, the company said.
“With so many drug names on the market, pharmaceutical brand owners face particularly complex challenges when developing new trademarks,” said Martin Burke, group managing director of Thomson CompuMark. “Expanding the coverage of our industry-leading Pharmaceutical XC Search is just the latest example of how Thomson Reuters keeps brand owners, and the IP professionals who advise them, ahead of the curve, providing the most complete information to help them make better decisions and reduce their business risk.”
Pharmaceutical XC Search offers:
· Exclusive search coverage of Thomson Reuters Micromedex, including international and FDA-approved drugs, as well as the Natural Medicines Database, the gold standard for natural medicines product information
· Additional FDA-recommended sources, including Drugs@FDA, AERS (Adverse Event Reporting System) and VAERS (Vaccine Adverse Event Reporting System) – important sources of brand names for which adverse events have been reported
· An authentic FDA POCA of Thomson CompuMark’s proprietary database featuring more than 90,000 drug names – the most extensive in the industry. Endorsed by the FDA, POCAs help clients identify potentially problematical names early in the clearance process, prior to FDA submission, by assessing the similarity of the mark in writing and speech, thereby reducing the risk of name rejection due to potential confusion
· New Citation Matrix showing the incidence of use for researched marks across the sources searched, offering additional insight on trademark use.